Safe Stop IPI-NIVO trial: early discontinuation of nivolumab upon achieving a complete or partial response in patients with irresectable stage III or metastatic melanoma treated with first-line ipilimumab-nivolumab – study protocol

J. C. Janssen, B. van Dijk,K. de Joode,M. J. B. Aarts,F. W. P. J. van den Berkmortel,C. U. Blank,M. J. Boers-Sonderen,A. J. M. van den Eertwegh,J. W. B. de Groot,M. Jalving,M. J. A. de Jonge,A. Joosse,E. Kapiteijn, A. M. Kamphuis-Huismans, K. A. T. Naipal,D. Piersma, B. Rikhof,H. M. Westgeest,G. Vreugdenhil,E. Oomen-de Hoop,E. E. A. P. Mulder,Astrid A. M. van der Veldt

BMC Cancer（2024）

引用 0|浏览10

暂无评分

摘要

Patients with irresectable stage III or metastatic melanoma presenting with poor prognostic factors are usually treated with a combination of immune checkpoint inhibitors (ICIs), consisting of ipilimumab and nivolumab. This combination therapy is associated with severe immune related adverse events (irAEs) in about 60

查看译文

关键词

Melanoma,Ipilimumab,Nivolumab,Discontinuation of treatment,Immune checkpoint inhibitors,Treatment duration

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要